Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Expedia Group Inc (EXPE) vs GeneDx Holdings Corp (WGS) Price & Performance

Expedia Group IncTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Expedia Group Inc vs GeneDx Holdings Corp — how do they compare? Expedia Group Inc trades at $323 (market cap $38.53B), while GeneDx Holdings Corp trades at $82.15 (market cap $2.44B). The key difference: Expedia Group Inc is far larger — about 15.8× GeneDx Holdings Corp's market cap, and Expedia Group Inc pays a 0.6% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

EXPEWGS
Market Cap
$38.53B$2.44B
Sector
Consumer CyclicalTechnology
52-Week High
$321.07$167.51
52-Week Low
$188.51$34.51
Enterprise Value
$37.09B$2.48B
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Expedia Group Inc

Expedia Group (EXPE) trades at $321.5, up 2.39% today, with strong technical momentum and a bullish moving average crossover. The company reported robust Q2 2026 earnings, beating estimates with EPS of $5.76 versus $5.22 expected, driven by 14% revenue growth and record adjusted EBITDA of $1.1 billion (Business Wire, 2026-08-05). Fundamentals show high profitability with a 90.43% gross margin and improving net income, while valuation ratios like P/E of 20.19 and P/S of 2.59 reflect market confidence.

Outlook is positive with raised full-year revenue guidance to $16.05B-$16.22B (WSJ, 2026-08-05), supported by AI and B2B growth. Risks include competitive pressures and economic sensitivity. Analysts are mixed but lean bullish with a $322.95 consensus target, near the current price, suggesting limited upside but stability.

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.

Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.

Returns comparison

Trailing returns across standard periods

About Expedia Group Inc

Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.

Read more on EXPE

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS